Please assess the completion status of the following clinical trial:

Trial Title: BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria~1. Patients scheduled to undergo a primary elective total hip or knee replacement.~2. Male of female being 18 years or older.~3. Patients weighing at least 40 kg.~4. Written informed consent for study participation.~Exclusion criteria~1. Bleeding diathesis, constitutional or acquired coagulation disorders.~2. Major surgery or trauma(e.g., hip fracture) within the last 3 months.~3. Cardiovascular disease~4. Any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral ischaemic attacks lasting more than 24 hours and / or with cardiovascular pathological findings.~5. Deep vein thrombosis(DVT), gastrointestinal or pulmonary bleeding, gastric or duodenal ulcer within the last year.~6. History of or acute intracranial disease~7. Liver disease~8. Renal disease~9. Use of long-term anticoagulants or antiplatelet drugs within 7 days prior to hip/knee replacement operation.~10. Pre-menopausal women who are not surgically steriles, are nursing and are of child-bearing potential and are not practising acceptable methods of birth control~11. Known allergy to contrast media~12. Thrombocytopenia~13. Allergy against heparin.~14. Active malignant disease or current cytostatic treatment.~15. Treatment with an investigational drug in the past month.~16. Leg amputee~17. Known alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBR 1048 50 mg bis in die(b.i.d) (Type: EXPERIMENTAL): BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
- BIBR 1048 150 mg b.i.d (Type: EXPERIMENTAL): BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
- BIBR 1048 225 mg b.i.d (Type: EXPERIMENTAL): BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
- BIBR 1048 300 mg quaque die(q.d) (Type: EXPERIMENTAL): BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
- Enoxaparin 40 mg subcutaneous(s.c) (Type: ACTIVE_COMPARATOR): placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).